Immuron making inroads into the international market with flagship assets Travelan and IMM-529
Australian biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) is making some big strides in its clinical programs, which is recently showcased…
0,023€
31,43%
Echtzeit-Aktienkurs IMMURON LTD
Bid:
Ask:
Nachrichten zur IMMURON LTD Aktie
Immuron welcomes NMRC results for campylobacter in controlled human infection model study
Globally integrated biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) says the US Naval Medical Research Command (NMRC) has wrapped up interim...…
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has received “favourable feedback” from the United States Food and Drug Administration (FDA) in support of…
Immuron nets A$3.5 million in funding from US Department of Defense for Travelan® research
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has received another ringing endorsement from the US Department of Defense (DOD) in the form of…
Immuron achieves record sales in FY2024 with 174% growth across markets
The commercialisation strategy of Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has borne abundant fruit in the 2024 financial year, garnering global sales income of...…
Immuron secures around US$2 million in funding after lodging Form F-3 and ATM prospectus with US SEC
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has secured an At-the-Market (ATM) funding facility with HC Wainwright and Co LLC, which will provide…
Immuron files pre-investigational new drug US FDA application for superbug fighting IMM-529
Australian-based and globally integrated biopharmaceutical company Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has filed a pre-IND (investigational new drug)...…
Immuron marks surge in Travelan® sales on eve of entry into US via Walmart.com
Immuron Ltd (NASDAQ:IMRN, ASX:IMC), a biopharmaceutical company headquartered in Australia, says sales of its immune supplement Travelan® have soared. Sales...…
Immuron to join exclusive list of ASX biotechs says Pitt Street Research
Having recently revealed interim topline results from its Phase 2 trial in Travelan, Immuron Ltd (NASDAQ:IMRN, ASX:IMC) is set to…
Immuron doubles on promising Travelan® Phase 2 results, advancing to Phase 3 trials in US
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has doubled on receiving positive interim topline results from its Phase 2 clinical trial of Travelan®, moving it…